Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
The European Commission approved Incyte's Povofortay (povorcitinib) 45 mg and 75 mg as the first once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa in the EU. Approval rests on the Phase 3 STOP-HS1 and STOP-HS2 trials, which met the HiSCR50 primary endpoint at Week 12, with durable responses through Week 54 (up to 71.4% HiSCR50, 57% HiSCR75, 29% HiSCR100) and no new safety signals.
Key figures
- Drug Name
- Povofortay (povorcitinib)
- Phase Of Trial
- Phase 3
- Hiscr75 max
- 57%
- Hiscr100 max
- 29%
- Doses approved mg
- [45,75]
- Hiscr50 week54 max
- 71.4%
- Us approval timing
- Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.